FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1908-1910 May 10, 2007 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Perspective Perspective by The FUTURE II Study Group Perspective by Garland, S. M. Editorial by Baden, L. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The FUTURE II Study Group Related Article by Garland, S. M. PubMed Citation

More than any other cancer, cervical cancer reflects striking global health inequity. It is the second most common cancer among women worldwide, with about 493,000 new cases diagnosed annually (see map). Of 274,000 deaths due to cervical cancer each year, more than 80% occur in developing countries, and this proportion is expected to increase to 90% by 2020.¹ Affecting relatively young women, it is the largest single cause of years of life lost to cancer in the developing world. The deaths of women who are in their most productive years have a devastating effect on the well-being of their . . . [Full Text of this Article]

Source Information

Dr. Agosti is a senior program officer for infectious diseases in the Global Health Program, Bill and Melinda Gates Foundation, Seattle. Dr. Goldie is a professor of health decision science in the Department of Health Policy and Management, Harvard School of Public Health, Boston.

Related Letters:

Human Papillomavirus Vaccine
Miller N. B., Raychaudhuri G., Toerner J. G., Suba E. J., Raab S. S., the Viet/American Cervical Cancer Prevention Project , Garland S. G., Koutsky L. A., Sawaya G. F., Smith-McCune K., Agosti J. M., Goldie S. J.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1154-1156, Sep 13, 2007. Correspondence

This article has been cited by other articles:

• Bian, T., Wang, Y., Lu, Z., Ye, Z., Zhao, L., Ren, J., Zhang, H., Ruan, L., Tian, H. (2008). Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Molecular Cancer Therapeutics 7: 1329-1335 [Abstract] [Full Text]  
• Chokshi, D. A, Kesselheim, A. S (2008). Rethinking global access to vaccines. BMJ 336: 750-753 [Full Text]  
• Outterson, K., Kesselheim, A. S. (2008). Market-Based Licensing For HPV Vaccines In Developing Countries. Health Aff (Millwood) 27: 130-139 [Abstract] [Full Text]  
• Miller, N. B., Raychaudhuri, G., Toerner, J. G., Suba, E. J., Raab, S. S., the Viet/American Cervical Cancer Prevention Proje, , Garland, S. G., Koutsky, L. A., Sawaya, G. F., Smith-McCune, K., Agosti, J. M., Goldie, S. J. (2007). Human Papillomavirus Vaccine. NEJM 357: 1154-1156 [Full Text]  
• Markowitz, L. E. (2007). HPV Vaccines Prophylactic, Not Therapeutic. JAMA 298: 805-806 [Full Text]  
• Baden, L. R., Curfman, G. D., Morrissey, S., Drazen, J. M. (2007). Human Papillomavirus Vaccine -- Opportunity and Challenge. NEJM 356: 1990-1991 [Full Text]  
• (2007). HPV Vaccination: Data at Last. JWatch General 2007: 1-1 [Full Text]